Searched for
NUTRACEUTICAL CONTRACT MANUFACTURING
Why Meta tapped Kunal Shah; Beauty’s new factory boomHappy Wednesday! Meta just handed WhatsApp’s steering wheel to Cred’s Kunal Shah, betting he can turn India’s favourite chat app into a pay...- Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal ManchandaIndia's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and ...
- For both the compulsive trader and careful investor: 25 stocks to watch if risk appetite returns; some with upside potential, some notIf the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...
- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- JM Financial Private Equity, family offices invest Rs 150 cr in NG Electro ProductsConsumer goods-focused NG Electro Products has secured Rs 150 crore in funding from JM Financial Private Equity and family offices. The cap...
- Sampre Nutrition inks 3-year manufacturing pact with Rama Exports for nutraceuticalsSampre Nutrition has partnered with Rama Exports in a manufacturing agreement to produce nutraceuticals and food products. Sampre Nutrition...
- Influx Healthtech shares list at 38% premium over IPO price on NSE SMEInflux Healthtech debuted strongly on the NSE SME platform, listing at Rs 132.5 per share, a 38% premium over its IPO price of Rs 96. The R...
- Influx Healthtech IPO subscribed over 41 times on Day 3; GMP signals strong listingInflux Healthtech's IPO witnessed an overwhelming response, being oversubscribed 41.07 times, driven by strong retail and NII participation...
- Influx Healthtech IPO subscribed 1.7 times on Day 1; GMP points to strong listing popInflux Healthtech IPO: In the unlisted market, Influx Healthtech’s grey market premium (GMP) was Rs 42 at 11:54 AM on Wednesday, suggesting...
- Influx Healthtech IPO opens today: Check key details before subscribingInflux Healthtech, a Mumbai-based CDMO, launches its IPO today, aiming to raise ₹55.63 crore through a fresh issue and offer-for-sale. The ...
- Kotak arm invests Rs 1,050 cr in Tirupati MedicareKotak Alternate Asset Managers has invested Rs 1,050 crore in Tirupati Medicare to support its expansion and provide a complete exit for Af...
- Kotak arm invests Rs 1,050 cr in Tirupati MedicareKotak Alternate Asset Managers announced a Rs 1,050-crore investment in Tirupati Medicare to aid its expansion, enabling a full exit for Af...
- Piramal Alternatives invests Rs 110 crore in Biodeal PharmaceuticalsPiramal Alternatives invested Rs 110 crore in Noida-based Biodeal Pharmaceuticals through convertible instruments. The funding will enhance...
- Vivanta jumps 5% on bagging LoI from Vitaanova Uganda for $5 mn projectThe project includes planning, designing, engineering, construction, supply, installation and commissioning of plant and machinery along wi...
- 65% jump in a month! Ruchi Soya seeks to add heft with healthy foodThe scrip soared 5 per cent to hit to settle at Rs 1,137.50 on Thursday.
- VAV Lifesciences to supply key COVID vaccine ingredient to Pfizer, ModernaMumbai-based VAV Lifesciences is the only domestic firm in the COVID-19 vaccine supply chain with this crucial ingredient. It can thus can ...
- Nutraceuticals sector executives raise concern over Biodiversity ActThe nutraceutical industry, which is at its nascent stage, offers significant socio-economic benefits with promising double-digit growth op...
- New farm laws will boost nutraceutical sector: Industry executivesIndia has a mere 2-3% share of the $400 billion global markets compared to China’s 14% because of a lack of standard guidelines and protoco...
- Nutraceuticals: The new $240-billion gold mine for Indian spicesThere are companies in India with over 100 patents for such products. Once they isolate a compound through research and clinical trials, th...
- Divi's Labs: Riding on strong client base, new capacitiesDivi's Labs, involved in contract research and manufacturing services (CRAMS), logged a robust performance for the fourth quarter ended Mar...
Load More
